Kura Oncology Reports Preliminary Proof of Mechanism in Phase 1/2 Clinical Trial of Tipifarnib Plus Alpelisib in Head and Neck Squamous Cell Carcinoma
26 oct. 2022 07h30 HE
|
Kura Oncology, Inc.
– First demonstration that precision combination therapies can achieve a durable clinical response in PIK3CA-dependent HNSCC – – Preclinical data support potential to address ~45% of HNSCC tumors...
PDS Biotech Chief Medical Officer Dr. Lauren V. Wood to Address 2022 International Head and Neck Conference
25 oct. 2022 08h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Oct. 25, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
$10.8 Billion Worldwide Radiation Oncology Industry to 2027 - Featuring Accuray, Canon, Elekta and Hitachi Among Others
28 sept. 2022 04h18 HE
|
Research and Markets
Dublin, Sept. 28, 2022 (GLOBE NEWSWIRE) -- The "Radiation Oncology Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ...
Heart Failure Therapeutics Market is expected to generate a revenue of USD 15 billion by 2029 Globally at a 3.8% CAGR
15 sept. 2022 06h08 HE
|
Exactitude Consultancy
Luton, Bedfordshire, United Kingdom, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Exactitude Consultancy, the market research and consulting wing of Ameliorate Digital Consultancy Private Limited has...
Global Oncology Nutrition Markets Report 2022-2026 - Ongoing Research and Development Initiatives Fuel Demand for Oncology Nutrition Products
15 avr. 2022 08h13 HE
|
Research and Markets
Dublin, April 15, 2022 (GLOBE NEWSWIRE) -- The "Oncology Nutrition - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global Oncology Nutrition...
Kura Oncology Announces Multiple Abstracts Accepted for Presentation at AACR Annual Meeting
08 mars 2022 17h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Vaccinex Announces $6.6 Million Private Placement
27 janv. 2022 16h15 HE
|
Vaccinex, Inc.
Participants include a syndicate of existing and new shareholdersContributes to total of $10.1 million in new equity financing for January, 2022 ROCHESTER, N.Y., Jan. 27, 2022 (GLOBE NEWSWIRE) --...
Kura Oncology Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma
16 déc. 2021 09h16 HE
|
Kura Oncology, Inc.
– Preclinical data suggest HRAS and PI3Kα are co-dependent oncogenes in HNSCC – – Combination has potential to address up to 50% of patients with HNSCC – – Initial cohort comprised of patients with...
PD-1 Resistant Head and Neck Cancer (HNC) Market Landscape Report 2021
31 août 2021 04h08 HE
|
Research and Markets
Dublin, Aug. 31, 2021 (GLOBE NEWSWIRE) -- The "PD-1 Resistant Head and Neck Cancer (HNC) - Market Insight, Epidemiology and Market Forecast 2030" report has been added to ResearchAndMarkets.com's...
Kura Oncology Announces Clinical Collaboration to Evaluate Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma
06 juil. 2021 07h30 HE
|
Kura Oncology, Inc.
– Combination of tipifarnib and alpelisib shows robust activity in preclinical PDX models of HRAS and PIK3CA pathway dependent tumors – – HNSCC accounts for more than 500,000 new cancer cases each...